Patent Grant
6872205
The present invention is a surgical device. More specifically, it is a circumferential ablation device assembly which is adapted to ablate a selected circumferential region of tissue along a pulmonary vein wall and thereby form a circumferential conduction block against conduction along the longitudinal axis of the pulmonary vein wall.
Many abnormal medical conditions in humans and other mammals have been associated with disease and other aberrations along the lining or walls which define several different body spaces. In order to treat such abnormal wall conditions of the body spaces, medical device technologies adapted for delivering specific forms of ablative energy to specific regions of targeted wall tissue from within the associated body space have been developed and disclosed.
The terms “body space,” including derivatives thereof, is herein intended to mean any cavity or lumen within the body which is defined at least in part by a tissue wall. For example, the cardiac chambers, the uterus, the regions of the gastrointestinal tract, and the arterial or venous vessels are all considered illustrative examples of body spaces within the intended meaning.
The term “lumen,” including derivatives thereof, is herein intended to mean any body space which is circumscribed along a length by a tubular tissue wall and which terminates at each of two ends in at least one opening that communicates externally of the body space. For example, the large and small intestines, the vas deferens, the trachea, and the fallopian tubes are all illustrative examples of lumens within the intended meaning. Blood vessels are also herein considered lumens, including regions of the vascular tree between their branch points. More particularly, the pulmonary veins are lumens within the intended meaning, including the region of the pulmonary veins between the branched portions of their ostia along a left ventricle wall, although the wall tissue defining the ostia typically presents uniquely tapered lumenal shapes.
Atherosclerosis, a vascular disease characterized by abnormal deposits upon vessel walls or thickening thereof, is an example of an abnormal wall condition. The dangers related to flow blockages or functional occlusions resulting from the disease have made atherosclerosis the focus of many disclosed devices. Such devices can be categorized by their structures and tissue treatment mechanisms. These categories may include direct contact electrode devices, resistance heating devices, light transmission/conversion-to-heat devices, hot fluid lumen devices, and radio frequency (RF) heated devices.
Several direct (or nearly direct) contact electrode devices have been disclosed. U.S. Pat. No. 4,998,933 to Eggers et al. describes a catheter designed for thermal angioplasty which utilizes a heated electrode in direct contact with surrounding tissue or plaque deposits as a mechanism for treating the diseased lumen walls. U.S. Pat. No. 4,676,258 to InoKuchi et al. and U.S. Pat. No. 4,807,620 to Strul et al. disclose devices designed to treat surrounding tissues using heat generated by two electrodes within the device and an RF power source.
U.S. Pat. No. 4,672,962 to Hershenson and U.S. Pat. No. 5,035,694 to Kasprzyk et al. disclose devices which may be categorized as resistance heating probes. In each of these devices, current flowing through a conductive material at the end of the device provides heat which is transmitted to surrounding tissues for treatment of atherosclerosis and other diseases. Current is transmitted in each of these devices by electrically conductive materials. In contrast, U.S. Pat. No. 5,226,430 to Spears et al. discloses a device which uses light transmitting fiber to transmit energy to a heat generating element at the tip of the device. The heat generating element in that device transmits heat energy to a surrounding balloon structure which is in contact with surrounding tissue. In further contrast, U.S. Pat. No. 4,790,311 to Ruiz discloses an angioplasty catheter system wherein a heat generating electrode at the tip of the device is heated using the transmission of RF energy. This device may be categorized as an RF heated device.
U.S. Pat. Nos. 5,190,540 and 5,292,321 to Lee can be categorized as hot fluid lumen devices. In the '540 disclosure, Lee describes a balloon catheter designed for remodelling a body lumen. This device utilizes a multilumen catheter which is capable of delivering heated fluid to an expandable balloon lumen, thereby expanding the balloon geometrically and heating tissue which is in contact with the balloon. In the '321 disclosure, Lee describes a similar device wherein the lumen of an expandable balloon is filled with thermoplastic material which is designed to become softer and more moldable when heated by a heating element.
Endometriosis, another abnormal wall tissue condition, is associated with the endometrial cavity of the female. This medical condition, characterized by dangerously proliferative uterine wall tissue along the surface of the endometrial cavity, has been treated by delivering energy to the tissue. U.S. Pat. No. 5,449,380 to Chin discloses a medical device for delivering energy to the wall tissue of a diseased endometrial cavity using a balloon lumen with heated fluid circulating therein. Other devices, such as those disclosed in U.S. Pat. No. 5,505,730 to Edwards; U.S. Pat. No. 5,558,672 to Edwards et al. and U.S. Pat. No. 5,562,720 to Stem et al. are designed for treating particular tissues using heat generated by the flow of RF current between electrodes.
Diseased or structurally damaged blood vessels may bring about various abnormal wall conditions. The inducement of thrombosis and control of hemorrhaging within certain body lumens such as vessels have been the focus of several disclosed devices which use catheter-based heat sources for cauterizing damaged tissues. In U.S. Pat. No. 4,449,528, for example, Auth et al. disclose a thermal cautery probe designed for heating specific layers of tissue without producing deep tissue damage. The mechanism of heat generation in this device is a resistive coil within the cautery probe which is electrically connected to a power source. In U.S. Pat. No. 4,662,368, Hussein et al. disclose a device designed for localized heat application within a lumen. In this device, energy for heat generation is delivered to the tip of the device in the form of light by a flexible fiber. Heat from an element which converts light energy to heat energy is then conducted to the adjacent tissue. In U.S. Pat. No. 4,522,205, Taylor et al. disclose a device designed for inducing thrombosis in a blood vessel comprising an array of electrodes mounted onto an expandable balloon which may be delivered by a catheter. The inventors of this device hypothesize that when direct current flows through electrodes which are in contact with adjacent tissues, thrombosis is precipitated.
Maintenance of patency in diseased lumens such as blood vessels has been the focus of several disclosed devices, several of which may be characterized as cardiovascular stents. U.S. Pat. No. 5,078,736 to Behl, for example, discloses an apparatus for maintaining patency in the body passages comprising a stent structure which may be connected to a radiofrequency power source. In addition to mechanically supporting a body lumen, this device may provide for thermal disruption of the adjacent tissues which may inhibit reocclusion of the lumen. U.S. Pat. No. 5,178,618 to Kandarpa discloses a similar device which may be used for recanalizing an occluded vessel prior to mechanically supporting a lumen region.
Atrial Fibrillation
Cardiac arrhythmias, and atrial fibrillation in particular, persist as common and dangerous medical ailments, especially in the aging population. In patients with normal sinus rhythm, the heart, which is comprised of atrial, ventricular, and excitatory conduction tissue, is electrically excited to beat in a synchronous, patterned fashion. In patients with cardiac arrhythmia, abnormal regions of cardiac tissue do not follow the synchronous beating cycle associated with normally conductive tissue in patients with sinus rhythm. Instead, the abnormal regions of cardiac tissue aberrantly conduct to adjacent tissue, thereby disrupting the cardiac cycle into an asynchronous cardiac rhythm. Such abnormal conduction has been previously known to occur at various regions of the heart, such as for example in the region of the sino-atrial (SA) node, along the conduction pathways of the atrioventricular (AV) node and the Bundle of His, or in the cardiac muscle tissue forming the walls of the ventricular and atrial cardiac chambers.
Cardiac arrhythmias, including atrial arrhythmia, may be of a multiwavelet reentrant type, characterized by multiple asynchronous loops of electrical impulses that are scattered about the atrial chamber and are often self propagating. In the alternative or in addition to the multiwavelet reentrant type, cardiac arrhythmias may also have a focal origin, such as when an isolated region of tissue in an atrium fires autonomously in a rapid, repetitive fashion. Cardiac arrhythmias, including atrial fibrillation, may be generally detected using the global technique of an electrocardiogram (EKG). More sensitive procedures of mapping the specific conduction along the cardiac chambers have also been disclosed, such as for example in U.S. Pat. No. 4,641,649 to Walinsky et al. and WO 96/32897 to Desai.
A host of clinical conditions may result from the irregular cardiac function and resulting hemodynamic abnormalities associated with atrial fibrillation, including stroke, heart failure, and other thromboembolic events. In fact, atrial fibrillation is believed to be a significant cause of cerebral stroke, wherein the abnormal hemodynamics in the left atrium caused by the fibrillatory wall motion precipitate the formation of thrombus within the atrial chamber. A thromboembolism is ultimately dislodged into the left ventricle, which thereafter pumps the embolism into the cerebral circulation where a stroke results. Accordingly, numerous procedures for treating atrial arrhythmias have been developed, including pharmacological, surgical, and catheter ablation procedures.
Conventional Atrial Arrhythmia Treatments
Several pharmacological approaches intended to remedy or otherwise treat atrial arrhythmias have been disclosed, such as, for example, in U.S. Pat. No. 4,673,563 to Berne et al.; U.S. Pat. No. 4,569,801 to Molloy et al.; and also by Hindricks, et al. in “Current Management of Arrhythmias” (1991). However, such pharmacological solutions are not generally believed to be entirely effective in many cases, and may in some cases result in proarrhythmia and long term inefficacy.
Several surgical approaches have also been developed with the intention of treating atrial fibrillation. One particular example is known as the “maze procedure,” as is disclosed by Cox, J L et al. in “The surgical treatment of atrial fibrillation. I. Summary” Thoracic and Cardiovascular Surgery 101(3), pp. 402-405 (1991); and also by Cox, J L in “The surgical treatment of atrial fibrillation. IV. Surgical Technique”, Thoracic and Cardiovascular Surgery 101(4), pp. 584-592 (1991). In general, the “maze” procedure is designed to relieve atrial arrhythmia by restoring effective atrial systole and sinus node control through a prescribed pattern of incisions about the tissue wall. In the early clinical experiences reported, the “maze” procedure included surgical incisions in both the right and the left atrial chambers. However, more recent reports predict that the surgical “maze” procedure may be substantially efficacious when performed only in the left atrium, such as is disclosed in Sueda et al., “Simple Left Atrial Procedure for Chronic Atrial Fibrillation Associated With Mitral Valve Disease” (1996).
The “maze procedure” as performed in the left atrium generally includes forming vertical incisions from the two superior pulmonary veins and terminating in the region of the mitral valve annulus, traversing the inferior pulmonary veins en route. An additional horizontal line also connects the superior ends of the two vertical incisions. Thus, the atrial wall region bordered by the pulmonary vein ostia is isolated from the other atrial tissue. In this process, the mechanical sectioning of atrial tissue eliminates the precipitating conduction to the atrial arrhythmia by creating conduction blocks within the aberrant electrical conduction pathways.
While the “maze” procedure as reported by Cox and others, and also other surgical procedures, have met some success in treating patients with atrial arrhythmia, its highly invasive methodology is believed to be prohibitive in most cases. However, these procedures have provided a guiding principle that mechanically isolating faulty cardiac tissue may successfully prevent atrial arrhythmia, and particularly atrial fibrillation caused by perpetually wandering reentrant wavelets or focal regions of arrhythmogenic conduction.
Modem Catheter Treatments for Atrial Arrhythmia
Success with surgical interventions through atrial segmentation, particularly with regard to the surgical “maze” procedure just described, has inspired the development of less invasive catheter-based approaches to treat atrial fibrillation through cardiac tissue ablation. Examples of such catheter-based devices and treatment methods have generally targeted atrial segmentation with ablation catheter devices and methods adapted to form linear or curvilinear lesions in the wall tissue which defines the atrial chambers, such as are disclosed in the following U.S. Patents: U.S. Pat. No. 5,617,854 to Munsif; U.S. Pat. No. 4,898,591 to Janget al.; U.S. Pat. No. 5,487,385 to Avitall; and U.S. Pat. No. 5,582,609 to Swanson. The disclosures of these patents are herein incorporated in their entirety by reference thereto.
Additional examples of catheter-based tissue ablation in performing less-invasive cardiac chamber segmentation procedures are also disclosed in the following articles: “Physics and Engineering of Transcatheter Tissue Ablation”, Avitall et al., Journal of American College of Cardiology, Volume 22, No. 3:921-932 (1993); and “Right and Left Atrial Radiofrequency Catheter Therapy of Paroxysmal Atrial Fibrillation,” Haissaguerre, et al., Journal of Cardiovascular Electrophysiology 7(12), pp. 1132-1144 (1996). These articles are herein incorporated in their entirety by reference thereto.
Furthermore, the use of particular guiding sheath designs for use in ablation procedures in both the right and/or left atrial chambers are disclosed in U.S. Pat. Nos. 5,427,119; 5,497,119; 5,564,440; 5,575,766 to Swartz et al. In addition, various energy delivery modalities have been disclosed for forming such atrial wall lesions, and include use of microwave, laser, and more commonly, radiofrequency energies to create conduction blocks along the cardiac tissue wall, as disclosed in WO 93/20767 to Stem et al.; U.S. Pat. No. 5,104,393 to Isner et al.; and U.S. Pat. No. 5,575,766 to Swartz et al, respectively. The disclosures of these references are herein incorporated in their entirety by reference thereto.
In addition to attempting atrial wall segmentation with long linear lesions for treating atrial arrhythmia, ablation catheter devices and methods have also been disclosed which are intended to ablate arrhythmogenic tissue of the left-sided accessory pathways, such as those associated with the Wolff-Parkinson-White syndrome, through the wall of an adjacent region along the coronary sinus.
For example, Fram et al., in “Feasibility of RF Powered Thermal Balloon Ablation of Atrioventricular Bypass Tracts via the Coronary Sinus: In vivo Canine Studies,” PACE, Vol. 18, p 1518-1530 (1995), disclose attempted thermal ablation of left-sided accessory pathways in dogs using a balloon which is heated with bipolar radiofrequency electrodes positioned within the balloon. A 10 French guiding catheter and a 0.035″ wire were provided in an assembly adapted to advance the ablation catheter into the coronary sinus from the jugular vein. Thermal ablation procedures were performed in the posterospetal coronary sinus and in the left free-wall coronary sinus with thermal inflations at either 70 deg, 80 deg, or 90 deg for either 30 or 60 seconds. In all cases balloon occlusion was confirmed using distal dye injection. A compliant silicone balloon was used which had a diameter range of 5-20 mm and a length range of 8-23 mm over a final inflation pressure range of 0.4 to 1.5 atms. Fram et al. discloses that the lesion depth of some population groups may be sufficient to treat patients with Wolff-Parkinson-White syndrome.
Additional examples of cardiac tissue ablation from the region of the coronary sinus for the purpose of treating particular types of cardiac arrhythmias are disclosed in: “Long-term effects of percutaneous laser balloon ablation from the canine coronary sinus”, Schuger C D et al., Circulation (1992) 86:947-954; and “Percutaneous laser balloon coagulation of accessory pathways”, McMath L P et al., Diagn Ther Cardiovasc Interven 1991; 1425:165-171.
Focal Arrhythmias Originating from Pulmonary Veins
Atrial fibrillation may be focal in nature, caused by the rapid and repetitive firing of an isolated center within the atrial cardiac muscle tissue. These foci, defined by regions exhibiting a consistent and centrifugal pattern of electrical activation, may act as either a trigger of atrial fibrillatory paroxysmal or may even sustain the fibrillation. Recent studies have suggested that focal arrhythmia often originates from a tissue region along the pulmonary veins of the left atrium, and even more particularly in the superior pulmonary veins.
Less-invasive percutaneous catheter ablation techniques have been disclosed which use end-electrode catheter designs with the intention of ablating and thereby treating focal arrhythmias in the pulmonary veins. These ablation procedures are typically characterized by the incremental application of electrical energy to the tissue to form focal lesions designed to interrupt the inappropriate conduction pathways.
One example of a focal ablation method intended to destroy and thereby treat focal arrhythmia originating from a pulmonary vein is disclosed by Haissaguerre, et al. in “Right and Left Atrial Radiofrequency Catheter Therapy of Paroxysmal Atrial Fibrillation” in Journal of Cardiovascular Electrophysiology 7(12), pp. 1132-1144 (1996). Haissaguerre, et al. disclose radiofrequency catheter ablation of drug-refractory paroxysmal atrial fibrillation using linear atrial lesions complemented by focal ablation targeted at arrhythmogenic foci in a screened patient population. The site of the arrhythmogenic foci were generally located just inside the superior pulmonary vein, and were ablated using a standard 4 mm tip single ablation electrode.
In another focal ablation example, Jais et al. in “A focal source of atrial fibrillation treated by discrete radiofrequency ablation” Circulation 95:572-576 (1997) applies an ablative technique to patients with paroxysmal arrhythmias originating from a focal source. At the site of arrhythmogenic tissue, in both right and left atria, several pulses of a discrete source of radiofrequency energy were applied in order to eliminate the fibrillatory process.
None of the cited references discloses a circumferential ablation device assembly which is adapted to form a circumferential conduction block around the circumference of a pulmonary vein wall in order to treat focal left atrial arrhythmias originating in the pulmonary vein.
Nor do the cited references disclose a circumferential ablation device with a circumferential ablation element that forms an equatorial band along the working length of an expandable element which has a length that is substantially less that the working length of the expandable element.
Nor do the cited references disclose a circumferential ablation device with an expandable member which has a shape when expanded that is adapted to conform to a pulmonary vein ostium along a left ventricular wall.
Nor do the cited references disclose a circumferential ablation device with an ablation element which circumscribes a radially compliant expandable element and which is adapted to form a continuous circumferential lesion in tissue over a working range of expanded diameters.
Nor do the cited references disclose a circumferential ablation device assembly that includes a circumferential ablation element on an expandable member and also a linear lesion ablation element adjacent to the expandable member.
The present invention is a circumferential ablation device assembly which is adapted to form a circumferential lesion along a circumferential path of tissue along a body space wall and which circumscribes a body space defined at least in part by the body space. The assembly includes an elongate body, an expandable member on the distal end portion of the elongate body which is adjustable from a radially collapsed position to a radially expanded position, and a circumferential ablation element that includes an equatorial or other circumferential band which circumscribes at least a portion of an outer surface of the working length of the expandable member when in the radially expanded position. The circumferential ablation element is adapted to ablate a circumferential region of tissue adjacent to the equatorial band and along the body space wall when the circumferential ablation element is coupled to and actuated by an ablation actuator.
In one variation, the equatorial band length is shorter than two-thirds the working length of the expandable member. In one mode of this variation, the ablation element includes a circumferential RF electrode in an RF ablation circuit. In another mode, the circumferential ablation electrode includes a porous membrane along the equatorial or other circumferential band which is adapted to pass electrically conductive fluid from the conductive fluid chamber and into tissue adjacent to the band, the fluid conducting current to the tissue in an RF ablation circuit. In still another mode, a thermal conductor is located along the equatorial band and is adapted to emit thermal energy into tissue adjacent to the equatorial band when the thermal conductor is coupled to and actuated by a thermal ablation actuator. In still a further mode, a pair of insulators may be positioned exteriorly of each of two ends of the circumferential ablation element, wherein the uninsulated space between the insulators forms the equatorial band which may be equatorially located or otherwise circumferentially located.
In another variation of the invention, a circumferential ablation member includes an expandable member with a working length which, when adjusted from a radially collapsed position to a radially expanded position, is adapted to conform to a pulmonary vein ostium. In one mode of this variation, the working length when expanded includes a taper with a distally reducing outer diameter from a proximal region to a distal region. In a further mode, the expandable member is radially compliant and is adapted to conform to the pulmonary vein ostium when the working length is expanded to the radially expanded position in the left atrium and the expandable member is thereafter forced retrogradedly against the pulmonary vein wall in the region of the pulmonary vein ostium.
In another variation of the invention, a circumferential ablation member includes an expandable member with a working length which is adjustable between a plurality of radially expanded positions each having a different expanded outer diameters in the region of the equatorial band. The equatorial band of the circumferential ablation element is adapted to ablate a continuous circumferential lesion pattern in tissue surrounding the equatorial band over the range of expanded outer diameters. In one mode of this variation, the equatorial band has a secondary shape along the outer surface of the working length, such as a modified step, serpentine, or sawtooth shape.
In another variation, the distal end portion of an elongate member includes a circumferential ablation member and also a linear ablation member having an elongate ablation element length and linear ablation element which is adapted to form a continuous linear lesion in tissue adjacent thereto when the linear ablation element is coupled to an ablation actuator. In a further mode of this variation, a first end of the linear ablation member is located adjacent to the expandable member which forms at least in part a first anchor adapted to secure the first linear ablation member end in the region of a pulmonary vein ostium along a left atrium wall. A second anchor is also provided adjacent to a second, opposite end of the linear ablation member end and is adapted to secure the second linear ablation member end to a second location along the left atrium wall.
As will be described with reference to the detailed embodiments below, the present invention is a circumferential ablation device assembly which is adapted to treat patients with atrial arrhythmia by forming a circumferential conduction block in a pulmonary vein which blocks electrical conduction along the longitudinal axis of the pulmonary vein wall and into the left atrium.
The terms “circumference” or “circumferential”, including derivatives thereof, are herein intended to mean a continuous path or line which forms an outer border or perimeter that surrounds and thereby defines an enclosed region of space. Such a continuous path starts at one location along the outer border or perimeter, and translates along the outer border or perimeter until it is completed at the original starting location to enclose the defined region of space. The related term “circumscribe,” including derivatives thereof, is herein intended to mean to enclose, surround, or encompass a defined region of space. Therefore, according to these defined terms, a continuous line which is traced around a region of space and which starts and ends at the same location “circumscribes” the region of space and has a “circumference” which is defined by the distance the line travels as it translates along the path circumscribing the space.
Still further, a circumferential path or element may include one or more of several shapes, and may be for example circular, oblong, ovular, elliptical, or otherwise planar enclosures. A circumferential path may also be three dimensional, such as for example two opposite-facing semi-circular paths in two different parallel or off-axis planes which are connected at their ends by line segments bridging between the planes.
For purpose of further illustration,
The term “transect”, including derivatives thereof, is also herein intended to mean to divide or separate a region of space into isolated regions. Thus, each of the regions circumscribed by the circumferential paths shown in
Therefore, a “circumferential conduction block” according to the present invention is formed along a region of tissue which follows a circumferential path along the pulmonary vein wall, circumscribing the pulmonary vein lumen and transecting the pulmonary vein relative to electrical conduction along its longitudinal axis. The transecting circumferential conduction block therefore isolates electrical conduction between opposite longitudinal portions of the pulmonary wall relative to the conduction block and along the longitudinal axis.
The terms “ablate” or “ablation,” including derivatives thereof, are hereafter intended to mean the substantial altering of the mechanical, electrical, chemical, or other structural nature of tissue. In the context of intracardiac ablation applications shown and described with reference to the variations of the illustrative embodiment below, “ablation” is intended to mean sufficient altering of tissue properties to substantially block conduction of electrical signals from or through the ablated cardiac tissue.
The term “element” within the context of “ablation element” is herein intended to mean a discrete element, such as an electrode, or a plurality of discrete elements, such as a plurality of spaced electrodes, which are positioned so as to collectively ablate a region of tissue.
Therefore, an “ablation element” according to the defined terms may include a variety of specific structures adapted to ablate a defined region of tissue. For example, one suitable ablation element for use in the present invention may be formed, according to the teachings of the embodiments below, from an “energy emitting” type which is adapted to emit energy sufficient to ablate tissue when coupled to and energized by an energy source. Suitable “energy emitting” ablation elements for use in the present invention may therefore include, for example: an electrode element adapted to couple to a direct current (“DC”) or alternating current (“AC”) current source, such as a radiofrequency (“RF”) current source; an antenna element which is energized by a microwave energy source; a heating element, such as a metallic element or other thermal conductor which is energized to emit heat such as by convective or conductive heat transfer, by resistive heating due to current flow, or by optical heating with light; a light emitting element, such as a fiber optic element which transmits light sufficient to ablate tissue when coupled to a light source; or an ultrasonic element such as an ultrasound crystal element which is adapted to emit ultrasonic sound waves sufficient to ablate tissue when coupled to a suitable excitation source.
In addition, other elements for altering the nature of tissue may be suitable as “ablation elements” under the present invention when adapted according to the detailed description of the invention below. For example, a cryoblation element adapted to sufficiently cool tissue to substantially alter the structure thereof may be suitable if adapted according to the teachings of the current invention. Furthermore, a fluid delivery element, such as a discrete port or a plurality of ports which are fluidly coupled to a fluid delivery source, may be adapted to infuse an ablating fluid, such as a fluid containing alcohol, into the tissue adjacent to the port or ports to substantially alter the nature of that tissue.
The term “diagnose”, including derivatives thereof, is intended to include patients suspected or predicted to have atrial arrhythmia, in addition to those having specific symptoms or mapped electrical conduction indicative of atrial arrhythmia.
In one aspect of using the circumferential ablation device assembly of the present invention, a patient diagnosed with multiple wavelet arrhythmia originating from multiple regions along the atrial wall is treated in part by forming the circumferential conduction block as an adjunct to forming long linear regions of conduction block between adjacent pulmonary vein ostia in a less-invasive “maze”-type catheter ablation procedure. More detail regarding particular ablation catheter embodiments adapted for use in such a method is provided below with reference to a combination circumferential-long linear lesion ablation device which is described below with reference to
A patient diagnosed with focal arrhythmia originating from an arrhythmogenic origin or focus in a pulmonary vein may also be treated with the circumferential ablation device assembly of the present invention by using the assembly to form a circumferential conduction block along a circumferential path of pulmonary vein wall tissue that either includes the arrhythmogenic origin or is between the origin and the left atrium. In the former case, the arrhythmogenic tissue at the origin is destroyed by the conduction block as it is formed through that focus. In the latter case, the arrhythmogenic focus may still conduct abnormally, although such aberrant conduction is prevented from entering and affecting the atrial wall tissue due to the intervening circumferential conduction block.
Further to positioning step (3) according to the method of
Once in the right atrium, the distal tip of the guiding catheter is positioned against the fossa ovalis in the intraatrial septal wall. A “Brochenbrough” needle or trocar is then advanced distally through the guide catheter until it punctures the fossa ovalis. A separate dilator may also be advanced with the needle through the fossa ovalis to prepare an access port through the septum for seating the guiding catheter. The guiding catheter thereafter replaces the needle across the septum and is seated in the left atrium through the fossa ovalis, thereby providing access for object devices through its own inner lumen and into the left atrium.
It is however further contemplated that other left atrial access methods may be suitable substitutes for using the circumferential ablation device assembly of the present invention. In one alternative variation not shown, a “retrograde” approach may be used, wherein the guiding catheter is advanced into the left atrium from the arterial system. In this variation, the Seldinger technique is employed to gain vascular access into the arterial system, rather than the venous, for example at a femoral artery. The guiding catheter is advanced retrogradedly through the aorta, around the aortic arch, into the ventricle, and then into the left atrium through the mitral valve.
Subsequent to gaining transeptal access to the left atrium as just described, positioning step (3) according to
Suitable guidewire designs for use in the overall circumferential ablation device assembly of the present invention may be selected from previously known designs, while generally any suitable choice should include a shaped, radiopaque distal end portion with a relatively stiff, torquable proximal portion adapted to steer the shaped tip under X-ray visualization. Guidewires having an outer diameter ranging from 0.010″ to 0.035″ may be suitable. In cases where the guidewire is used to bridge the atrium from the guiding catheter at the fossa ovalis, and where no other sub-selective guiding catheters are used, guidewires having an outer diameter ranging from 0.018″ to 0.035″ may be required. It is believed that guidewires within this size range may be required to provide sufficient stiffness and maneuverability in order to allow for guidewire control and to prevent undesirable guidewire prolapsing within the relatively open atrial cavity.
Subsequent to gaining pulmonary vein access, positioning step (3) of
More specifically,
As would be apparent to one of ordinary skill, the distal guidewire tracking member shown in FIG. 3 and just described may be slideably coupled to the guidewire externally of the body in a “backloading” technique after the guidewire is first positioned in the pulmonary vein. Furthermore, there is no need in this guidewire tracking variation for a guidewire lumen in the proximal portions of the elongate catheter body (130), which allows for a reduction in the outer diameter of the catheter shaft in that region. Nevertheless, it is further contemplated that a design which places the second distal guidewire port on the proximal end portion of the elongate catheter body would also be acceptable, as is described below for example with reference to the perfusion embodiment of FIG. 5.
In addition, the inclusion of a guidewire lumen extending within the elongate body between first and second ports, as provided in
While the assemblies and methods shown variously throughout the Figures include a guidewire coupled to a guidewire tracking member on the circumferential ablation catheter, other detailed variations may also be suitable for positioning the circumferential ablation element at the ablation region in order to form a circumferential conduction block there. For example, an alternative circumferential ablation catheter not shown may include a “fixed-wire”-type of design wherein a guidewire is integrated into the ablation catheter as one unit. In another alternative assembly, the same type of sub-selective sheaths described above with reference to U.S. Pat. No. 5,575,766 to Swartz for advancing a guidewire into a pulmonary vein may also be used for advancing a circumferential ablation catheter device across the atrium and into a pulmonary vein.
Circumferential ablation element (160) also includes a circumferential band (152) on the outer surface of working length L which is coupled to an ablation actuator (190) at a proximal end portion of the elongate catheter body (shown schematically). After expandable member (170) is adjusted to the radially expanded position and at least a portion of working length L circumferentially engages the pulmonary vein wall in the ablation region, the circumferential band (152) of the circumferential ablation element (160) is actuated by ablation actuator (190) to ablate the surrounding circumferential path of tissue in the pulmonary vein wall, thereby forming a circumferential lesion that circumscribes the pulmonary vein lumen and transects the electrical conductivity of the pulmonary vein to block conduction in a direction along its longitudinal axis.
Further to the perfusion design shown in
In another alternative perfusion variation not shown which is a modification of the embodiment of
Passive perfusion during expansion of the expandable member is believed to minimize stasis and allow the target pulmonary vein to continue in its atrial filling function during the atrial arrhythmia treatment procedure. Without this perfusion feature, the expandable member when in the radially expanded position during ablation blocks the flow from the vein into the atrium, which flow stasis may result in undesirable thrombogenesis in the pulmonary vein distally to the expandable member. In addition, in cases where the ablation element is adapted to ablate tissue with heat conduction at the ablation region, as described by reference to more detailed embodiments below, the perfusion feature according to the variation of
Moreover, in addition to the specific perfusion structure shown and described by reference to
It is believed, however, that circumferential catheter ablation with a circumferential ablation element according to the present invention may leave some tissue, either transmurally or along the circumference of the lesion, which is not actually ablated, but which is not substantial enough to allow for the passage of conductive signals. Therefore, the terms “transmural” and “continuous” as just defined are intended to have functional limitations, wherein some tissue in the ablation region may be unablated but there are no functional gaps which allow for symptomatically arrhythmogenic signals to conduct through the conduction block and into the atrium from the pulmonary vein.
Moreover, it is believed that the functionally transmural and continuous lesion qualities just described are characteristic of a completed circumferential conduction block in the pulmonary vein. Such a circumferential conduction block thereby transects the vein, isolating conduction between the portion of the vein on one longitudinal side of the lesion and the portion on the other side. Therefore, any foci of originating arrhythmogenic conduction which is opposite the conduction block from the atrium is prevented by the conduction block from conducting down into the atrium and atrial arrhythmic affects are therefore nullified.
More specifically,
In a further variation to the specific embodiments shown in
A shaped stylet (466) is shown in shadow in
In addition or in the alternative to monitoring electrical conduction signals in the pulmonary vein prior to ablation, electrical signals along the pulmonary vein wall may also be monitored by the sensing element subsequent to circumferential ablation, according to step (9) of the method of FIG. 9. This monitoring method aids in testing the efficacy of the ablation in forming a complete conduction block against arrhythmogenic conduction. Arrhythmogenic firing from the identified focus will not be observed during signal monitoring along the pulmonary vein wall when taken below a continuous circumferential and transmural lesion formation, and thus would characterize a successful circumferential conduction block. In contrast, observation of such arrhythmogenic signals between the lesion and the atrial wall characterizes a functionally incomplete or discontinuous circumference (gaps) or depth (transmurality) which would potentially identify the need for a subsequent follow-up procedure, such as a second circumferential lesioning procedure in the ablation region.
A test electrode may also be used in a “post ablation” signal monitoring method according to step (10) of FIG. 9. In one particular embodiment not shown, the test electrode is positioned on the distal end portion of an elongate catheter body and is electrically coupled to a current source for firing a test signal into the tissue surrounding the test electrode when it is placed distally or “upstream” of the circumferential lesion in an attempt to simulate a focal arrhythmia. This test signal generally challenges the robustness of the circumferential lesion in preventing atrial arrhythmia from any such future physiologically generated aberrant activity along the suspect vein.
Further to the signal monitoring and test stimulus methods just described, such methods may be performed with a separate electrode or electrode pair located on the catheter distal end portion adjacent to the region of the circumferential ablation element, or may be performed using one or more electrodes which form the circumferential ablation element itself, as will be further developed below.
Circumferential Ablation Member
The designs for the expandable member and circumferential ablation element for use in the circumferential ablation device assembly of the present invention have been described generically with reference to the embodiments shown in the previous Figures. Examples of more specific expandable member and ablation element embodiments which are adapted for use in the assembly of the present invention are further provided as follows.
Notwithstanding their somewhat schematic detail, the circumferential ablation members shown in the previous figures do illustrate one particular embodiment wherein a circumferential electrode element circumscribes an outer surface of an expandable member. The expandable member of the embodiments shown may take one of several different forms, although the expandable member is generally herein shown as an inflatable balloon that is coupled to an expansion actuator (175) which is a pressurizeable fluid source. The balloon is preferably made of a polymeric material and forms a fluid chamber which communicates with a fluid passageway (not shown in the figures) that extends proximally along the elongate catheter body and terminates proximally in a proximal fluid port that is adapted to couple to the pressurizeable fluid source.
In one expandable balloon variation, the balloon is constructed of a relatively inelastic polymer such as a polyethylene (“PE”; preferably linear low density or high density or blends thereof), polyolefin copolymer (“POC”), polyethylene terepthalate (“PET”), polyimide, or a nylon material. In this construction, the balloon has a low radial yield or compliance over a working range of pressures and may be folded into a predetermined configuration when deflated in order to facilitate introduction of the balloon into the desired ablation location via known percutaneous catheterization techniques. In this variation, one balloon size may not suitably engage all pulmonary vein walls for performing the circumferential ablation methods of the present invention on all needy patients. Therefore, it is further contemplated that a kit of multiple ablation catheters, with each balloon working length having a unique predetermined expanded diameter, may be provided from which a treating physician may chose a particular device to meet a particular patient's pulmonary vein anatomy.
In an alternative expandable balloon variation, the balloon is constructed of a relatively compliant, elastomeric material, such as, for example (but not limited to), a silicone, latex, or mylar elastomer. In this construction, the balloon takes the form of a tubular member in the deflated, non-expanded state. When the elastic tubular balloon is pressurized with fluid such as in the previous, relatively non-compliant example, the material forming the wall of the tubular member elastically deforms and stretches radially to a predetermined diameter for a given inflation pressure. It is further contemplated that the compliant balloon may be constructed as a composite, such as for example a latex or silicone balloon skin which includes fibers, such as metal, Kevlar, or nylon fibers, which are embedded into the skin. Such fibers, when provided in a predetermined pattern such as a mesh or braid, may provide a controlled compliance along a preferred axis, preferably limiting longitudinal compliance of the expandable member while allowing for radial compliance.
It is believed that, among other features, the relatively compliant variation may provide a wide range of working diameters, which may allow for a wide variety of patients, or of vessels within a single patient, to be treated with just one or a few devices. Furthermore, this range of diameters is achievable over a relatively low range of pressures, which is believed to diminish a potentially traumatic vessel response that may otherwise be presented concomitant with higher pressure inflations, particularly when the inflated balloon is oversized to the vessel. In addition, the low-pressure inflation feature of this variation is suitable for the present invention because the functional requirement of the expandable balloon is merely to engage the ablation element against a circumferential path along the inner lining of the pulmonary vein wall.
Moreover, a circumferential ablation member is adapted to conform to the geometry of the pulmonary vein ostium, at least in part by providing substantial compliance to the expandable member, as was shown and described previously by reference to
Further to the circumferential electrode element embodiment as shown variously throughout the previous illustrative Figures, the circumferential electrode element is coupled to an ablation actuator (190). Ablation actuator (190) generally includes a radio-frequency (“RP”) current source (not shown) that is coupled to both the RF electrode element and also a ground patch (195) which is in skin contact with the patient to complete an RF circuit. In addition, ablation actuator (190) preferably includes a monitoring circuit (not shown) and a control circuit (not shown) which together use either the electrical parameters of the RF circuit or tissue parameters such as temperature in a feedback control loop to drive current through the electrode element during ablation. Also, where a plurality of ablation elements or electrodes in one ablation element are used, a switching means may be used to multiplex the RF current source between the various elements or electrodes.
The shapes shown collectively in
In addition, the electrode band provided by the circumferential ablation elements shown in
In another aspect of the narrow equatorial band variation for the circumferential ablation element, the circumferential lesion formed may also be relatively narrow when compared to its own circumference, and may be less than two-thirds or even one-half its own circumference on the expandable element when expanded. In one arrangement which is believed to be suitable for ablating circumferential lesions in the pulmonary veins as conduction blocks, the band width w is less than 1 cm with a circumference on the working length when expanded that is greater than 1.5 cm.
The size and spacing between these individual electrode elements (562), when the balloon is expanded, is adapted to form a substantially continuous circumferential lesion in pulmonary vein wall tissue when in intimal contact adjacent thereto, and is further adapted to form such a lesion over a range of band diameters as the working length is adjusted between a variety of radially expanded positions. Each individual electrode element (562) has two opposite ends (563,564), respectively, along a long axis LA and also has a short axis SA, and is positioned such that the long axis LA is at an acute angle relative to the longitudinal axis La of the elongate catheter body and expandable member (560). At least one of the ends (563,564) along the long axis LA overlaps with an end of another adjacent individual electrode element, such that there is a region of overlap along their circumferential aspect, i.e., there is a region of overlap along the circumferential coordinates. The terms “region of overlap along their circumferential coordinate” are herein intended to mean that the two adjacent ends each are positioned along the working length with a circumferential and also a longitudinal coordinate, wherein they share a common circumferential coordinate. In this arrangement, the circumferential compliance along the working length which accompanies radial expansion of the expandable member also moves the individual electrode elements apart along the circumferential axis. However, the spaced, overlapping arrangement described allows the individual ablation elements to maintain a certain degree of their circumferential overlap, or at least remain close enough together, such that a continuous lesion may be formed without gaps between the elements.
The construction for suitable circumferential electrode elements in the RF variation of the present invention, such as the various electrode embodiments described with reference to
Still further to the RF electrode embodiments, another circumferential ablation member variation (not shown) may also include an expandable member, such as an inflatable balloon, that includes a porous skin that is adapted to allow fluid, such as hypertonic saline solution, to pass from an internal chamber defined by the skin and outwardly into surrounding tissues. Such a porous skin may be constructed according to several different methods, such as by forming holes in an otherwise contiguous polymeric material, including mechanically drilling or using laser energy, or the porous skin may simply be an inherently porous membrane. In any case, by electrically coupling the fluid within the porous balloon skin to an RF current source (preferably monopolar), the porous region of the expandable member serves as an RF electrode wherein RF current flows outwardly through the pores via the conductive fluid. In addition, it is further contemplated that a porous outer skin may be provided externally of another, separate expandable member, such as a separate expandable balloon, wherein the conductive fluid is contained in a region between the porous outer skin and the expandable member contained therein. Various other “fluid electrode” designs than those specifically herein described may also be suitable according to one of ordinary skill upon review of this disclosure.
In the alternative, or in addition to the RF electrode variations just described, the circumferential ablation element may also include other ablative energy sources or sinks, and particularly may include a thermal conductor that circumscribes the outer circumference of the working length of an expandable member. Examples of suitable thermal conductor arrangements include a metallic element which may for example be constructed as previously described for the more detailed RF embodiments above. However, in the thermal conductor embodiment such a metallic element would be generally either resistively heated in a closed loop circuit internal to the catheter, or conductively heated by a heat source coupled to the thermal conductor. In the latter case of conductive heating of the thermal conductor with a heat source, the expandable member may be for example a polymeric balloon skin which is inflated with a fluid that is heated either by a resistive coil or by bipolar RF current. In any case, it is believed that a thermal conductor on the outer surface of the expandable member is suitable when it is adapted to heat tissue adjacent thereto to a temperature between 40 deg and 80 deg Celsius.
Further to the thermal conduction variation for the circumferential ablation element, the perfusion balloon embodiment as shown in
One further circumferential ablation element design which is believed to be highly useful in performing the methods according to the present invention is shown in
The thermal insulator embodiment just described by reference to
In a further example using the insulator embodiment in combination with a circumferential RF electrode embodiment, a metallized balloon which includes a conductive balloon skin may have an electrical insulator, such as a polymeric coating, at each end of the working length and thereby selectively ablate tissue with electricity flowing through the uninsulated equatorial band. In this and other insulator embodiments, it is further contemplated that the insulators described may be only partial and still provide the equatorial band result. For instance, in the conductive RF electrode balloon case, a partial electrical insulator will allow a substantial component of current to flow through the uninsulated portion due to a “shorting” response to the lower resistance in that region.
In still a further example of an insulator combined with an RF ablation electrode, a porous membrane comprises the entire balloon skin of an expandable member. By insulating the proximal and distal end portions of the working length of the expandable member, only the pores in the unexposed equatorial band region are allowed to effuse the electrolyte which carries an ablative RF current.
Further to the expandable member design for use in a circumferential ablation element according to the present invention, other expandable members than a balloon are also considered suitable. For example, in one expandable cage embodiment shown in
The radial expansion of cage (650) is accomplished as follows. Sheath (652) is secured around the wires proximally of cage (650). However, core (653), which may be a metallic mandrel such as stainless steel, extends through sheath (652) and distally within cage (650) wherein it terminates in a distal tip (656). Wires (651) are secured to distal tip (656), for example by soldering, welding, adhesive bonding, heat shrinking a polymeric member over the wires, or any combination of these methods. Core (653) is slideable within sheath (652), and may for example be housed within a tubular lumen (not shown) within sheath (652), the wires being housed between a coaxial space between the tubular lumen and sheath (652). By moving the sheath (652) relative to core (653) and distal tip (656)(shown by arrows in FIG. 13), the cage (650) is collapsible along its longitudinal axis in order to force an outward radial bias (also shown with arrows in
Further to the particular expandable cage embodiment shown in
Further to the construction of the embodiment shown in
In a further cage embodiment (not shown) to that shown in
Another circumferential ablation element adapted for use in the circumferential conduction block assembly according to the present invention is shown in
Looped member (710) is shown in more detail in
Pusher (730) is further shown in
While particular detailed description has been herein provided for particular embodiments and variations according to the present invention, it is further understood that various modifications and improvements may be made by one of ordinary skill according to this disclosure and without departing from the broad scope of the invention.
This application is a continuation of U.S. application Ser. No. 09/642,614 filed on Aug. 17, 2000, now U.S. Pat. No. 6,416,511, which is a continuation of U.S. application Ser. No. 09/273,815 filed on Mar. 22, 1999, now U.S. Pat. No. 6,254,599, which is a continuation of U.S. application Ser. No. 08/889,798 filed on Jul. 8, 1997, now U.S. Pat. No. 6,024,740, and a continuation-in-part of U.S. application Ser. No. 08/853,861 filed on May 9, 1997, now U.S. Pat. No. 5,971,983.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3565062 | Kurls | Feb 1971 | A |
| 3938502 | Bom | Feb 1976 | A |
| 4033031 | Ballew | Jul 1977 | A |
| 4117836 | Erikson | Oct 1978 | A |
| 4316472 | Mirowski et al. | Feb 1982 | A |
| 4354497 | Kahn | Oct 1982 | A |
| 4411266 | Cosman | Oct 1983 | A |
| 4449528 | Auth et al. | May 1984 | A |
| 4522205 | Taylor et al. | Jun 1985 | A |
| 4565200 | Cosman | Jan 1986 | A |
| 4569801 | Molloy et al. | Feb 1986 | A |
| 4616333 | Shimoni | Oct 1986 | A |
| 4637392 | Sorochenko | Jan 1987 | A |
| 4641649 | Walinsky et al. | Feb 1987 | A |
| 4660571 | Hess et al. | Apr 1987 | A |
| 4662368 | Hussein et al. | May 1987 | A |
| 4669469 | Gifford, III et al. | Jun 1987 | A |
| 4672962 | Hershenson | Jun 1987 | A |
| 4673563 | Berne et al. | Jun 1987 | A |
| 4676258 | Inokuchi et al. | Jun 1987 | A |
| 4699147 | Chilson et al. | Oct 1987 | A |
| 4757820 | Itoh | Jul 1988 | A |
| 4762129 | Bonzel | Aug 1988 | A |
| 4790311 | Ruiz | Dec 1988 | A |
| 4790317 | Davies | Dec 1988 | A |
| 4799493 | DuFault | Jan 1989 | A |
| 4807620 | Strul et al. | Feb 1989 | A |
| 4841977 | Griffith et al. | Jun 1989 | A |
| 4882777 | Narula | Nov 1989 | A |
| 4898591 | Jang et al. | Feb 1990 | A |
| 4920980 | Jackowski | May 1990 | A |
| 4924863 | Sterzer | May 1990 | A |
| 4932413 | Shockey et al. | Jun 1990 | A |
| 4936281 | Stasz | Jun 1990 | A |
| 4940064 | Desai | Jul 1990 | A |
| 4945912 | Langberg | Aug 1990 | A |
| 4951677 | Crowley et al. | Aug 1990 | A |
| 4974598 | John | Dec 1990 | A |
| 4976711 | Parins et al. | Dec 1990 | A |
| 4998933 | Eggers et al. | Mar 1991 | A |
| 5000185 | Yock | Mar 1991 | A |
| 5002059 | Crowley et al. | Mar 1991 | A |
| 5007908 | Rydell | Apr 1991 | A |
| 5035694 | Kasprzyk et al. | Jul 1991 | A |
| 5058599 | Andersen | Oct 1991 | A |
| 5074313 | Dahl et al. | Dec 1991 | A |
| 5078717 | Parins et al. | Jan 1992 | A |
| 5078736 | Behl | Jan 1992 | A |
| 5090958 | Sahota | Feb 1992 | A |
| 5100423 | Fearnot | Mar 1992 | A |
| 5103821 | King | Apr 1992 | A |
| 5104393 | Isner et al. | Apr 1992 | A |
| 5107850 | Olive | Apr 1992 | A |
| 5131397 | Crowley | Jul 1992 | A |
| 5147355 | Friedman et al. | Sep 1992 | A |
| 5156157 | Valenta, Jr. et al. | Oct 1992 | A |
| 5158079 | Adams et al. | Oct 1992 | A |
| 5178618 | Kandarpa | Jan 1993 | A |
| 5178620 | Eggers et al. | Jan 1993 | A |
| 5186177 | O'Donnell et al. | Feb 1993 | A |
| 5190540 | Lee | Mar 1993 | A |
| 5195990 | Weldor | Mar 1993 | A |
| 5209229 | Gilli | May 1993 | A |
| 5222501 | Ideker et al. | Jun 1993 | A |
| 5226430 | Spears et al. | Jul 1993 | A |
| 5228442 | Imran | Jul 1993 | A |
| 5231994 | Harmjanz | Aug 1993 | A |
| 5231995 | Desai | Aug 1993 | A |
| 5255679 | Imran | Oct 1993 | A |
| 5259395 | Li | Nov 1993 | A |
| 5263493 | Avitall | Nov 1993 | A |
| 5275162 | Edwards et al. | Jan 1994 | A |
| 5281215 | Milder | Jan 1994 | A |
| 5292321 | Lee | Mar 1994 | A |
| 5293868 | Nardella | Mar 1994 | A |
| 5293869 | Edwards et al. | Mar 1994 | A |
| 5295484 | Marcus et al. | Mar 1994 | A |
| 5300085 | Yock | Apr 1994 | A |
| 5311873 | Savard et al. | May 1994 | A |
| 5313943 | Houser et al. | May 1994 | A |
| 5314460 | Borghi | May 1994 | A |
| 5314461 | Borghi | May 1994 | A |
| 5324255 | Passafaro et al. | Jun 1994 | A |
| 5324284 | Imran | Jun 1994 | A |
| 5325860 | Seward et al. | Jul 1994 | A |
| 5331966 | Bennett et al. | Jul 1994 | A |
| 5336222 | Durgin, Jr. et al. | Aug 1994 | A |
| 5336251 | Borghi | Aug 1994 | A |
| 5342292 | Nita et al. | Aug 1994 | A |
| 5342357 | Nardella | Aug 1994 | A |
| 5344435 | Turner et al. | Sep 1994 | A |
| 5345936 | Pomeranz et al. | Sep 1994 | A |
| 5345940 | Seward et al. | Sep 1994 | A |
| 5348554 | Imran et al. | Sep 1994 | A |
| 5366486 | Zipes et al. | Nov 1994 | A |
| 5366487 | Adams et al. | Nov 1994 | A |
| 5366490 | Edwards et al. | Nov 1994 | A |
| 5368035 | Hammet et al. | Nov 1994 | A |
| 5368557 | Nita et al. | Nov 1994 | A |
| 5368558 | Nita | Nov 1994 | A |
| 5370675 | Edwards et al. | Dec 1994 | A |
| 5370678 | Edwards et al. | Dec 1994 | A |
| 5372138 | Crowley et al. | Dec 1994 | A |
| 5374285 | Vaiani et al. | Dec 1994 | A |
| 5383876 | Nardella | Jan 1995 | A |
| 5385148 | Lesh et al. | Jan 1995 | A |
| 5385544 | Edwards et al. | Jan 1995 | A |
| 5391197 | Burdette et al. | Feb 1995 | A |
| 5391199 | Ben-Haim | Feb 1995 | A |
| 5400796 | Wecke | Mar 1995 | A |
| 5403311 | Abele et al. | Apr 1995 | A |
| 5405376 | Mulier et al. | Apr 1995 | A |
| 5409000 | Imran | Apr 1995 | A |
| 5409453 | Lundquist et al. | Apr 1995 | A |
| 5411524 | Rahul | May 1995 | A |
| 5421338 | Crowley et al. | Jun 1995 | A |
| 5421819 | Edwards et al. | Jun 1995 | A |
| 5423808 | Edwards et al. | Jun 1995 | A |
| 5423811 | Imran et al. | Jun 1995 | A |
| 5427119 | Swartz et al. | Jun 1995 | A |
| 5431649 | Mulier et al. | Jul 1995 | A |
| 5433198 | Desai | Jul 1995 | A |
| 5433708 | Nichols et al. | Jul 1995 | A |
| 5435805 | Edwards et al. | Jul 1995 | A |
| 5437664 | Cohen et al. | Aug 1995 | A |
| 5439483 | Duong-Van | Aug 1995 | A |
| 5443456 | Alliger et al. | Aug 1995 | A |
| 5443489 | Ben-Haim | Aug 1995 | A |
| 5447509 | Mills et al. | Sep 1995 | A |
| 5449380 | Chin | Sep 1995 | A |
| 5450846 | Goldreyer | Sep 1995 | A |
| 5454373 | Koger et al. | Oct 1995 | A |
| 5456682 | Edwards et al. | Oct 1995 | A |
| 5464431 | Adams et al. | Nov 1995 | A |
| 5470308 | Edwards et al. | Nov 1995 | A |
| 5474530 | Passafaro et al. | Dec 1995 | A |
| 5476503 | Yang | Dec 1995 | A |
| 5482037 | Borghi | Jan 1996 | A |
| 5484400 | Edwards et al. | Jan 1996 | A |
| 5485849 | Panescu et al. | Jan 1996 | A |
| 5487385 | Avitall | Jan 1996 | A |
| 5496312 | Klicek | Mar 1996 | A |
| 5496346 | Horzewski et al. | Mar 1996 | A |
| 5496360 | Hoffmann et al. | Mar 1996 | A |
| 5497119 | Tedrow et al. | Mar 1996 | A |
| 5497774 | Swartz et al. | Mar 1996 | A |
| 5498238 | Shapland et al. | Mar 1996 | A |
| 5500012 | Brucker et al. | Mar 1996 | A |
| 5501227 | Yock | Mar 1996 | A |
| 5505702 | Arney | Apr 1996 | A |
| 5505730 | Edwards | Apr 1996 | A |
| 5507802 | Imran | Apr 1996 | A |
| 5509900 | Kirkman | Apr 1996 | A |
| 5522873 | Jackman et al. | Jun 1996 | A |
| 5540679 | Fram et al. | Jul 1996 | A |
| 5545161 | Imran | Aug 1996 | A |
| 5545193 | Fleischman et al. | Aug 1996 | A |
| 5549603 | Feiring | Aug 1996 | A |
| 5549641 | Ayers et al. | Aug 1996 | A |
| 5549661 | Kordis et al. | Aug 1996 | A |
| 5558672 | Edwards et al. | Sep 1996 | A |
| 5558720 | Sarraf et al. | Sep 1996 | A |
| 5562720 | Stern et al. | Oct 1996 | A |
| 5564440 | Swartz et al. | Oct 1996 | A |
| 5571088 | Lennox et al. | Nov 1996 | A |
| 5571159 | Alt | Nov 1996 | A |
| 5575766 | Swartz et al. | Nov 1996 | A |
| 5575772 | Lennox | Nov 1996 | A |
| 5575788 | Baker et al. | Nov 1996 | A |
| 5575810 | Swanson et al. | Nov 1996 | A |
| 5582609 | Swanson et al. | Dec 1996 | A |
| 5588432 | Crowley | Dec 1996 | A |
| 5605159 | Smith et al. | Feb 1997 | A |
| 5606974 | Castellano et al. | Mar 1997 | A |
| 5607422 | Smeets et al. | Mar 1997 | A |
| 5607462 | Imran | Mar 1997 | A |
| 5609151 | Mulier et al. | Mar 1997 | A |
| 5617854 | Munsif | Apr 1997 | A |
| 5620479 | Diederich | Apr 1997 | A |
| 5630837 | Crowley | May 1997 | A |
| 5642736 | Avitall | Jul 1997 | A |
| 5645082 | Sung et al. | Jul 1997 | A |
| 5658278 | Imran et al. | Aug 1997 | A |
| 5661133 | Leiden et al. | Aug 1997 | A |
| 5673695 | McGee et al. | Oct 1997 | A |
| 5674274 | Morgan et al. | Oct 1997 | A |
| 5676153 | Smith et al. | Oct 1997 | A |
| 5676662 | Fleischhacker et al. | Oct 1997 | A |
| 5680860 | Imran | Oct 1997 | A |
| 5681308 | Edwards et al. | Oct 1997 | A |
| 5682885 | Littmann et al. | Nov 1997 | A |
| 5683445 | Swoyer | Nov 1997 | A |
| 5685322 | Sung et al. | Nov 1997 | A |
| 5685839 | Edwards et al. | Nov 1997 | A |
| 5687723 | Avitall | Nov 1997 | A |
| 5687729 | Schaetzle | Nov 1997 | A |
| 5688267 | Panescu et al. | Nov 1997 | A |
| 5690611 | Swartz et al. | Nov 1997 | A |
| 5693078 | Desai et al. | Dec 1997 | A |
| 5693622 | Wolff et al. | Dec 1997 | A |
| 5697925 | Taylor | Dec 1997 | A |
| 5697927 | Imran et al. | Dec 1997 | A |
| 5702438 | Avitall | Dec 1997 | A |
| 5715818 | Swartz et al. | Feb 1998 | A |
| 5716389 | Walinsky et al. | Feb 1998 | A |
| 5718231 | Dewhurst et al. | Feb 1998 | A |
| 5718241 | Ben-Haim et al. | Feb 1998 | A |
| 5718701 | Shai et al. | Feb 1998 | A |
| 5720775 | Lamard | Feb 1998 | A |
| 5722401 | Pietroski et al. | Mar 1998 | A |
| 5722403 | McGee et al. | Mar 1998 | A |
| 5722963 | Lurie et al. | Mar 1998 | A |
| 5725494 | Brisken | Mar 1998 | A |
| 5725512 | Swartz et al. | Mar 1998 | A |
| 5728062 | Brisken | Mar 1998 | A |
| 5730127 | Avitall | Mar 1998 | A |
| 5730704 | Avitall | Mar 1998 | A |
| 5733315 | Burdette et al. | Mar 1998 | A |
| 5735280 | Sherman et al. | Apr 1998 | A |
| 5735811 | Brisken | Apr 1998 | A |
| 5735846 | Panescu et al. | Apr 1998 | A |
| 5741249 | Moss et al. | Apr 1998 | A |
| 5741320 | Thornton et al. | Apr 1998 | A |
| 5743870 | Edwards | Apr 1998 | A |
| 5743903 | Stern et al. | Apr 1998 | A |
| 5755663 | Larsen et al. | May 1998 | A |
| 5755664 | Rubenstein | May 1998 | A |
| 5755715 | Stern et al. | May 1998 | A |
| 5755760 | Maguire et al. | May 1998 | A |
| 5769846 | Edwards et al. | Jun 1998 | A |
| 5782239 | Webster, Jr. | Jul 1998 | A |
| 5782898 | Dahl et al. | Jul 1998 | A |
| RE35880 | Waldman et al. | Aug 1998 | E |
| 5797842 | Pumares et al. | Aug 1998 | A |
| 5797877 | Hamilton et al. | Aug 1998 | A |
| 5797903 | Swanson et al. | Aug 1998 | A |
| 5797905 | Fleischman et al. | Aug 1998 | A |
| 5800378 | Edwards et al. | Sep 1998 | A |
| 5800379 | Edwards | Sep 1998 | A |
| 5800413 | Swartz et al. | Sep 1998 | A |
| 5800428 | Nelson et al. | Sep 1998 | A |
| 5800429 | Edwards | Sep 1998 | A |
| 5800432 | Swanson | Sep 1998 | A |
| 5807249 | Qin et al. | Sep 1998 | A |
| 5807308 | Edwards | Sep 1998 | A |
| 5807391 | Wijkamp | Sep 1998 | A |
| 5807395 | Mulier et al. | Sep 1998 | A |
| 5836874 | Swanson et al. | Nov 1998 | A |
| 5840031 | Crowley | Nov 1998 | A |
| 5840076 | Swanson et al. | Nov 1998 | A |
| 5842984 | Avitall | Dec 1998 | A |
| 5843154 | Osypka | Dec 1998 | A |
| 5846218 | Brisken et al. | Dec 1998 | A |
| 5860974 | Abele | Jan 1999 | A |
| 5885278 | Fleischman | Mar 1999 | A |
| 5921982 | Lesh et al. | Jul 1999 | A |
| 5938660 | Swartz et al. | Aug 1999 | A |
| 5971983 | Lesh | Oct 1999 | A |
| 6001093 | Swanson et al. | Dec 1999 | A |
| 6012457 | Lesh | Jan 2000 | A |
| 6024740 | Lesh et al. | Feb 2000 | A |
| 6064902 | Haissaguerre et al. | May 2000 | A |
| 6071279 | Whayne et al. | Jun 2000 | A |
| 6071281 | Burnside et al. | Jun 2000 | A |
| 6071282 | Fleischman | Jun 2000 | A |
| 6090084 | Hassett et al. | Jul 2000 | A |
| 6117101 | Diederich et al. | Sep 2000 | A |
| 6146379 | Fleischman et al. | Nov 2000 | A |
| 6161543 | Cox et al. | Dec 2000 | A |
| 6164283 | Lesh | Dec 2000 | A |
| 6171306 | Swanson et al. | Jan 2001 | B1 |
| 6214002 | Fleischman et al. | Apr 2001 | B1 |
| 6235025 | Swartz et al. | May 2001 | B1 |
| 6237605 | Vaska et al. | May 2001 | B1 |
| 6254599 | Lesh et al. | Jul 2001 | B1 |
| Number | Date | Country |
|---|---|---|
| 296 09 350 | Aug 1996 | DE |
| 195 37 084 | Apr 1997 | DE |
| 0 149 431 | Jul 1985 | EP |
| 0 452 278 | Oct 1991 | EP |
| 0 452 278 | Oct 1991 | EP |
| 0 472 368 | Feb 1992 | EP |
| 0 609 182 | Aug 1994 | EP |
| 0 711 573 | Nov 1994 | EP |
| 0 672 431 | Sep 1995 | EP |
| 0 672 432 | Sep 1995 | EP |
| 0 711 573 | May 1996 | EP |
| WO 9300958 | Jan 1993 | WO |
| WO 9308755 | May 1993 | WO |
| WO 9316632 | Sep 1993 | WO |
| WO 9320767 | Oct 1993 | WO |
| WO 9320770 | Oct 1993 | WO |
| WO 9320787 | Oct 1993 | WO |
| WO 9320886 | Oct 1993 | WO |
| WO 9400050 | Jan 1994 | WO |
| WO 9421165 | Sep 1994 | WO |
| WO 9421167 | Sep 1994 | WO |
| WO 9421168 | Sep 1994 | WO |
| WO 9505781 | Mar 1995 | WO |
| WO 9510318 | Apr 1995 | WO |
| WO 9510319 | Apr 1995 | WO |
| WO 9510321 | Apr 1995 | WO |
| WO 9515115 | Jun 1995 | WO |
| WO 9519738 | Jul 1995 | WO |
| WP 9519738 | Jul 1995 | WO |
| WO 9600036 | Jan 1996 | WO |
| WO 9610961 | Apr 1996 | WO |
| WO 9626675 | Sep 1996 | WO |
| WO 9632885 | Oct 1996 | WO |
| WO 9632897 | Oct 1996 | WO |
| WO 9732525 | Sep 1997 | WO |
| WO 9737607 | Oct 1997 | WO |
| WO 9745156 | Dec 1997 | WO |
| WO 9802201 | Jan 1998 | WO |
| PCTUS9814220 | Nov 1998 | WO |
| WO 9849957 | Nov 1998 | WO |
| WO 9900064 | Jan 1999 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20020115995 A1 | Aug 2002 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 09642614 | Aug 2000 | US |
| Child | 10133523 | US | |
| Parent | 09273815 | Mar 1999 | US |
| Child | 09642614 | US | |
| Parent | 08889798 | Jul 1997 | US |
| Child | 09273815 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 08853861 | May 1997 | US |
| Child | 08889798 | US |
